Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) For Patients With Severe COVID-19
Retrieved on:
Monday, August 3, 2020
"Our lead compound, NTR-441, and other molecules from our Chromatinase platform are the only drugs currently in development that could systemically remove NETs from the body.
Key Points:
- "Our lead compound, NTR-441, and other molecules from our Chromatinase platform are the only drugs currently in development that could systemically remove NETs from the body.
- In patients with severe COVID-19, the circulating levels of DNASE1L3 are not adequate to counteract the rapid and systemic formation of NETs.
- NTR-441 has the potential to systemically clear NETs in the vasculature and end organs like the lungs in patients suffering from severe COVID-19.
- Neutrolis' proprietary platform, Chromatinase, is based on the naturally occurring enzymes that break down the extracellular chromatin that form NETs.